title: Synthesis and bioactivity of fatty acid-conjugated GnRH derivatives.
abstract: Transdermal delivery of peptidic drugs is usually inefficient, notably due to their hydrophilic character which makes it difficult to cross the hydrophobic layers of the skin. In order to obtain transdermally deliverable analogs of gonadotropin releasing hormone (GnRH), we have synthesized related hydrophobic derivatives by attaching various aliphatic acids to the N(epsilon)-amino side chain of [D-Lys]6GnRH, a superactive GnRH agonist. It was found that the affinity toward the GnRH receptor gradually decrease with increased hydrophobicity, i.e. increase in chain length of the attached aliphatic acid. Nevertheless, analogs with 12-carbon or shorter aliphatic acids were shown to be GnRH superagonists, with in vitro and in vivo potencies similar to that of [D-Lys]6GnRH. [D-Lys-lauryl]6GnRH was shown to have a longer duration of action in vivo, as compared to [D-Lys]6GnRH. The transdermal penetration of the peptides was evaluated by in vivo functional experiments in rats. According to these studies the efficiency of penetration is gradually lowered in increasingly hydrophobic analogs. These results are discussed with respect to the circular dichroism spectra of the peptides in trifluoroethanol. The spectra of the aliphatic acid-conjugated superagonists examined do not express a significant tendency towards a beta-turn conformation, typical of GnRH and its agonists. This finding contradict previous publications which suggested a correlation between the conformations of GnRH analogs in trifluoroethanol and their biological activities.
authors.affiliation: Department of Neurobiology, Weizmann Institute of Science, Rehovot, Israel. lhdror@weizmann.weizmann.ac.il
authors.forename: D
authors.initials: D
authors.lastname: Yahalom
authors.forename: Y
authors.initials: Y
authors.lastname: Koch
authors.forename: N
authors.initials: N
authors.lastname: Ben-Aroya
authors.forename: M
authors.initials: M
authors.lastname: Fridkin
mesh_terms: D000279:Administration, Cutaneous; D000818:Animals; D002942:Circular Dichroism; D005227:Fatty Acids / Q000008:administration & dosage*; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000494:pharmacology; D007986:Luteinizing Hormone / Q000378:metabolism; D011487:Protein Conformation; D051381:Rats; D017208:Rats, Wistar; D011966:Receptors, LHRH / Q000378:metabolism; D012867:Skin / Q000378:metabolism*; D012995:Solubility
chemical_list: D005227:Fatty Acids; D011966:Receptors, LHRH; D007987:Gonadotropin-Releasing Hormone; D007986:Luteinizing Hormone